HDAC9 and lymphoma: Several recent reports have shown that the expression of TRAIL or TRAIL-receptors was induced by HDAC inhibitors in leukaemia cells, breast and colon cancer cells [24-28], while other studies have reported no change in the expression level of DR4, DR5 and DcR2 in melanoma and lymphoma cells [31,37].